Skip to main content

Table 2 Summary of decision-tree inputs

From: Clinical and economic impact of current ALK rearrangement testing in Spain compared with a hypothetical no-testing scenario

 

Input

Reference

ALK determination strategies

 IHC

37.2%

[18]

 FISH

11.6%

[18]

 Reflex

46.5%

[18]

 NGS

4.7%

[18]

Positivity rate in selected biomarkers

 ALK+

3.4%

[18]

 EGFR+

13.6%

[18]

 ROS1+

2%

[18]

 PD-L1 ≥ 50%

33%

[18]

 Percentage of invalid results

 With IHC or FISH

2.6%

[18]

 With NGS

3.4%

[19]

Rebiopsy

 Probability of rebiopsy if invalid

77.1%

[20]

Specificity and sensitivity

 IHC

97.9% / 96.8%

[21]

 FISH

99.8% / 90.9%

[22]

 NGS

100%

Assumptiona

  1. ALK anaplastic lymphoma kinase, IHC immunohistochemistry, FISH fluorescent in situ hybridization, NGS next-generation sequencing, EGFR epidermal growth factor receptor
  2. aConsidered the gold standard in the determination of ALK